High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an eff ective treatment for elderly patients with poor-prognosis lymphoma

被引：17

作者：

Martin, Nicolas ^{[1
]}

Borchiellini, Delphine ^{[1
]}

Coso, Diane ^{[2
]}

Gastaud, Lauris ^{[1
]}

Boscagli, Annick ^{[1
]}

Saudes, Laurence ^{[3
]}

Re, Daniel ^{[4
]}

Gutnecht, Jean ^{[5
]}

Garnier, Georges ^{[6
]}

Petit, Emmanuel ^{[7
]}

Barriere, Jerome ^{[8
]}

Naman, Herve ^{[9
]}

Rossignol, Benoit ^{[10
]}

Thyss, Antoine ^{[1
]}

Peyrade, Frederic ^{[1
]}

机构：

[1] Ctr Antoine Lacassagne, Dept Oncol, F-06189 Nice 2, France

[2] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[3] Cannes Hosp, Dept Oncol, Cannes, France

[4] Antibes Juan Les Pins Hosp, Dept Oncol, Nice, France

[5] Frejus St Raphael Hosp, Dept Oncol, Nice, France

[6] Princesse Grace Hosp Ctr, Dept Oncol, Monaco, Monaco

[7] Oxford Clin, Dept Oncol, Cannes, France

[8] St Jean Polyclin, Dept Oncol, Cagnes Sur Mer, France

[9] Azurean Ctr Oncol, Mougins, France

[10] La Dracenie Hosp Ctr, Draguignan, France

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 08期

关键词：

Autologous stem cell transplant; lymphoma; elderly; BEAM; NON-HODGKINS-LYMPHOMA; PATIENTS GREATER-THAN-OR-EQUAL-TO-60 YEARS; PROSPECTIVE RANDOMIZED-TRIAL; DETUDE-DES-LYMPHOMES; PRIMARY CNS LYMPHOMA; MULTIPLE-MYELOMA; R-CHOP; AGGRESSIVE LYMPHOMA; EUROPEAN-BLOOD; OLDER PATIENTS;

D O I：

10.3109/10428194.2014.1001987

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Autologous stem cell transplant (ASCT) after high-dose chemotherapy (HDT) increases overall survival when used in relapsed non-Hodgkin lymphoma (NHL) in patients under 65 years old. Limited experience is available for older patients. We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT. Patient data were obtained from medical charts from two institutions. Median age was 67 years (65-74). Significant comorbidities were present in 24.7% of patients. The median number of days for grade 4 neutropenia was 9 (5-18). The early treatment-related mortality rate (< 100 days) was 2.7%. The estimated 2-year progression-free survival and overall survival rates were 67.2% and 78.5%, respectively. In conclusion, the full-dose HDT-ASCT regimen is feasible, safe and efficient in selected patients over 65 years old.

引用

页码：2379 / 2387

页数：9

共 54 条

[1] Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis [J].

Abrey, LE ;

Moskowitz, CH ;

Mason, WP ;

Crump, M ;

Stewart, D ;

Forsyth, P ;

Paleologos, N ;

Correa, DD ;

Anderson, ND ;

Caron, D ;

Zelenetz, A ;

Nimer, SD ;

DeAngelis, LM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4151-4156

[2] Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) [J].

Advani, Ranjana H. ;

Chen, Haiyan ;

Habermann, Thomas M. ;

Morrison, Vicki A. ;

Weller, Edie A. ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Gascoyne, Randy D. ;

Horning, Sandra J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (02) :143-151

[3]

[Anonymous], ANN M FRENCH SOC BON

[4]

[Anonymous], BLOOD S1

[5] High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma [J].

Bitran, JD ;

Klein, L ;

Link, D ;

Kosirog-Glowacki, J ;

Stewart, C ;

Raack, D ;

Sheahan, P ;

Lisowski, J ;

Rowen, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (06) :383-388

[6] Prospective Oral Mucositis Audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European blood and marrow transplantation mucositis advisory group [J].

Blijlevens, Nicole ;

Schwenkglenks, Matthias ;

Bacon, Pamela ;

D'Addio, Alessandra ;

Einsele, Hermann ;

Maertens, Johan ;

Niederwieser, Dietger ;

Rabitsch, Werner ;

Roosaar, Ann ;

Ruutu, Tapani ;

Schouten, Harry ;

Stone, Rebecca ;

Vokurka, Samuel ;

Quinn, Barry ;

McCann, Shaun .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1519-1525

[7] Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma [J].

Buadi, F. K. ;

Micallef, I. N. ;

Ansell, S. M. ;

Porrata, L. F. ;

Dispenzieri, A. ;

Elliot, M. A. ;

Gastineau, D. A. ;

Gertz, M. A. ;

Lacy, M. Q. ;

Litzow, M. R. ;

Tefferi, A. ;

Inwards, D. J. .

BONE MARROW TRANSPLANTATION, 2006, 37 (11) :1017-1022

[8]

Chan WC, 1997, BLOOD, V89, P3909

[9] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[10] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

← 1 2 3 4 5 6 →